Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical SettingsReport as inadecuate




Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings - Download this document for free, or read online. Document in PDF available to download.

ISRN Neurology - Volume 2014 2014, Article ID 956353, 10 pages -

Clinical Study

QPS Netherlands B.V., Petrus Campersingel 123, 9713 AG Groningen, P.O. Box 137, 9700 AC Groningen, The Netherlands

Synthon B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands

Received 11 November 2013; Accepted 10 December 2013; Published 22 January 2014

Academic Editors: G. Boysen, G. Meco, and T. Müller

Copyright © 2014 Khalid Abou Farha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Dopamine D2 receptor agonists represent a first line treatment option in young patients with signs and symptoms of idiopathic Parkinson’s disease. An association between the use of D2 receptor agonists in Parkinson’s disease patients and heart failure has been reported. The identification of the underlying mechanism is needed to minimize the resultant cardiovascular morbidity. In a phase I clinical trial, a D2 receptor agonist pramipexole was administered to 52 healthy male subjects following a dose escalation scheme. Serial measurements of resting blood pressure, heart rate, and derived parameters including pulse pressure, pulsatile stress, and rate pressure product were analysed. Statistically significant and clinically relevant increases in most of the assessed parameters were found. Ten subjects were removed prematurely from the trial because of clinically significant increases in blood pressure and-or heart rate requiring immediate intervention with IV rescue medications including a selective β-1 blocker. The observed drug-related changes in vital signs were of clinical relevance and might explain some of the cardiovascular morbidity reported in patients receiving D2 receptor agonist in clinical settings. We suggest that the additional use of a β-1 blocking agent might mitigate the risk of cardiovascular morbidity among patients receiving long-term D2 receptor agonists.





Author: Khalid Abou Farha, Corine Baljé-Volkers, Wim Tamminga, Izaak den Daas, and Sandra van Os

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents